Oncology Medical Director, Clinical Development (Hybrid SF)

Meet Life Sciences; San Francisco (CA); Hybrid; USD 180,000 - 220,000; Full time

Benefits offered by this job

Competitive compensation package

Meaningful strategic input

Visibility with senior leadership

Job summary

A cutting-edge biotech firm in the San Francisco Bay Area seeks an Associate Medical Director or Medical Director to drive oncology clinical development initiatives. The ideal candidate is a clinically practicing oncologist or physician with 1-2 years in biotech/pharma. This pivotal role offers the chance to contribute to late-stage clinical programs and offers visibility with senior leadership. A competitive compensation package awaits motivated professionals looking to make a significant impact in oncology.

Qualifications

• Board-certified/eligible preferred in oncology.
• Direct patient care experience is necessary.
• Understanding of oncology drug development.

Responsibilities

• Contribute to clinical development strategy across oncology programs.
• Lead or support protocol design and study oversight.
• Provide medical monitoring and scientific leadership.
• Author and review clinical and regulatory documents.
• Engage with KOLs, investigators, and advisory boards.
• Collaborate with Clinical Operations and Regulatory teams.

Skills

Hands-on clinical experience treating patients

Excellent communication skills

Scientific rigor

Stakeholder engagement

Entrepreneurial mindset

Education

MD (or equivalent) with oncology training

Job description

A cutting-edge biotech firm in the San Francisco Bay Area seeks an Associate Medical Director or Medical Director to drive oncology clinical development initiatives. The ideal candidate is a clinically practicing oncologist or physician with 1-2 years in biotech/pharma. This pivotal role offers the chance to contribute to late-stage clinical programs and offers visibility with senior leadership. A competitive compensation package awaits motivated professionals looking to make a significant impact in oncology.